Insider Selling: Elliot Ehrich Sells 7,718 Shares of Alkermes PLC Stock (ALKS)
Alkermes PLC (NASDAQ:ALKS) CMO Elliot Ehrich sold 7,718 shares of Alkermes PLC stock on the open market in a transaction dated Tuesday, January 21st. The stock was sold at an average price of $48.61, for a total transaction of $375,171.98. Following the completion of the sale, the chief marketing officer now directly owns 16,579 shares in the company, valued at approximately $805,905. The transaction was disclosed in a filing with the SEC, which can be accessed through this link.
A number of analysts have recently weighed in on ALKS shares. Analysts at Leerink Swann raised their price target on shares of Alkermes PLC from $42.00 to $46.00 in a research note to investors on Monday, December 16th. Separately, analysts at Zacks reiterated a “neutral” rating on shares of Alkermes PLC in a research note to investors on Monday, December 16th. They now have a $41.00 price target on the stock. Finally, analysts at UBS AG downgraded shares of Alkermes PLC to a “neutral” rating in a research note to investors on Friday, December 6th. Four investment analysts have rated the stock with a sell rating, eight have issued a hold rating and one has given a strong buy rating to the company’s stock. The stock has an average rating of “Hold” and a consensus price target of $35.86.
Alkermes PLC (NASDAQ:ALKS) traded up 2.00% on Wednesday, hitting $50.52. The stock had a trading volume of 1,624,214 shares. Alkermes PLC has a 1-year low of $19.77 and a 1-year high of $48.42. The stock has a 50-day moving average of $41.64 and a 200-day moving average of $35.73. The company has a market cap of $6.909 billion and a price-to-earnings ratio of 361.53.
Alkermes PLC (NASDAQ:ALKS) last issued its quarterly earnings data on Thursday, October 31st. The company reported $0.22 EPS for the quarter, meeting the Thomson Reuters consensus estimate of $0.22. The company had revenue of $139.80 million for the quarter, compared to the consensus estimate of $137.35 million. During the same quarter in the prior year, the company posted $0.17 earnings per share. The company’s quarterly revenue was up 12.7% on a year-over-year basis.
Alkermes plc., formerly Alkermes, Inc, is an integrated biotechnology company. The Company is engaged in the business of developing, manufacturing and commercializing medicines for the treatment of prevalent, chronic diseases.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.